Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia

Karen K. Ballen; Ann E. Woolfrey; Xiaochun Zhu; Kwang Woo Ahn; Baldeep Wirk; Mukta Arora; Biju George; Bipin N. Savani; Brian Bolwell; David L. Porter; Ed Copelan; Gregory Hale; Harry C. Schouten; Ian Lewis; Jean Yves Cahn; Joerg Halter; Jorge Cortes; Matt E. Kalaycio; Joseph Antin; Mahmoud D. Aljurf; Matthew H. Carabasi; Mehdi Hamadani; Philip McCarthy; Steven Pavletic; Vikas Gupta; H. Joachim Deeg; Richard T. Maziarz; Mary M. Horowitz; Wael Saber

doi:10.1016/j.bbmt.2012.03.009

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia

Karen K. Ballen, Ann E. Woolfrey, Xiaochun Zhu, Kwang Woo Ahn, Baldeep Wirk, Mukta Arora, Biju George, Bipin N. Savani, Brian Bolwell, David L. Porter, Ed Copelan, Gregory Hale, Harry C. Schouten, Ian Lewis, Jean Yves Cahn, Joerg Halter, Jorge Cortes, Matt E. Kalaycio, Joseph Antin, Mahmoud D. AljurfMatthew H. Carabasi, Mehdi Hamadani, Philip McCarthy, Steven Pavletic, Vikas Gupta, H. Joachim Deeg, Richard T. Maziarz, Mary M. Horowitz, Wael Saber

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS.

Original language	English (US)
Pages (from-to)	1446-1454
Number of pages	9
Journal	Biology of Blood and Marrow Transplantation
Volume	18
Issue number	9
DOIs	https://doi.org/10.1016/j.bbmt.2012.03.009
State	Published - Sep 2012

Bibliographical note

Funding Information:
The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI) , and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI ; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from Allos, Inc. ; Amgen, Inc. ; Angioblast; anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.

Keywords

ET
PV
Transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.bbmt.2012.03.009

Find It

Find It at U of M Libraries

Cite this

Ballen, K. K., Woolfrey, A. E., Zhu, X., Ahn, K. W., Wirk, B., Arora, M., George, B., Savani, B. N., Bolwell, B., Porter, D. L., Copelan, E., Hale, G., Schouten, H. C., Lewis, I., Cahn, J. Y., Halter, J., Cortes, J., Kalaycio, M. E., Antin, J., ... Saber, W. (2012). Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia. Biology of Blood and Marrow Transplantation, 18(9), 1446-1454. https://doi.org/10.1016/j.bbmt.2012.03.009

Ballen, KK, Woolfrey, AE, Zhu, X, Ahn, KW, Wirk, B, Arora, M, George, B, Savani, BN, Bolwell, B, Porter, DL, Copelan, E, Hale, G, Schouten, HC, Lewis, I, Cahn, JY, Halter, J, Cortes, J, Kalaycio, ME, Antin, J, Aljurf, MD, Carabasi, MH, Hamadani, M, McCarthy, P, Pavletic, S, Gupta, V, Deeg, HJ, Maziarz, RT, Horowitz, MM & Saber, W 2012, 'Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia', Biology of Blood and Marrow Transplantation, vol. 18, no. 9, pp. 1446-1454. https://doi.org/10.1016/j.bbmt.2012.03.009

@article{a4edad70291547b6b43c3e3c5f38c0b6,

title = "Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia",

abstract = "Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS.",

keywords = "ET, PV, Transplantation",

author = "Ballen, {Karen K.} and Woolfrey, {Ann E.} and Xiaochun Zhu and Ahn, {Kwang Woo} and Baldeep Wirk and Mukta Arora and Biju George and Savani, {Bipin N.} and Brian Bolwell and Porter, {David L.} and Ed Copelan and Gregory Hale and Schouten, {Harry C.} and Ian Lewis and Cahn, {Jean Yves} and Joerg Halter and Jorge Cortes and Kalaycio, {Matt E.} and Joseph Antin and Aljurf, {Mahmoud D.} and Carabasi, {Matthew H.} and Mehdi Hamadani and Philip McCarthy and Steven Pavletic and Vikas Gupta and Deeg, {H. Joachim} and Maziarz, {Richard T.} and Horowitz, {Mary M.} and Wael Saber",

note = "Funding Information: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI) , and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI ; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from Allos, Inc. ; Amgen, Inc. ; Angioblast; anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.",

year = "2012",

month = sep,

doi = "10.1016/j.bbmt.2012.03.009",

language = "English (US)",

volume = "18",

pages = "1446--1454",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia

AU - Ballen, Karen K.

AU - Woolfrey, Ann E.

AU - Zhu, Xiaochun

AU - Ahn, Kwang Woo

AU - Wirk, Baldeep

AU - Arora, Mukta

AU - George, Biju

AU - Savani, Bipin N.

AU - Bolwell, Brian

AU - Porter, David L.

AU - Copelan, Ed

AU - Hale, Gregory

AU - Schouten, Harry C.

AU - Lewis, Ian

AU - Cahn, Jean Yves

AU - Halter, Joerg

AU - Cortes, Jorge

AU - Kalaycio, Matt E.

AU - Antin, Joseph

AU - Aljurf, Mahmoud D.

AU - Carabasi, Matthew H.

AU - Hamadani, Mehdi

AU - McCarthy, Philip

AU - Pavletic, Steven

AU - Gupta, Vikas

AU - Deeg, H. Joachim

AU - Maziarz, Richard T.

AU - Horowitz, Mary M.

AU - Saber, Wael

N1 - Funding Information: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI) , and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI ; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from Allos, Inc. ; Amgen, Inc. ; Angioblast; anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.

PY - 2012/9

Y1 - 2012/9

N2 - Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS.

AB - Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS.

KW - ET

KW - PV

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84865198731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865198731&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.03.009

DO - 10.1016/j.bbmt.2012.03.009

M3 - Article

C2 - 22449610

AN - SCOPUS:84865198731

SN - 1083-8791

VL - 18

SP - 1446

EP - 1454

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 9

ER -

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this